GT Biopharma, Inc. (GTBP), a San Francisco-based clinical-stage immuno-oncology company, is followed by only a handful of analysts, so the $75 figure must be understood carefully. As of late October 2026, Yahoo Finance, Investing.com, and TradingView each displayed a single one-year analyst price target of $75.00, while Longbridge and Futu showed the same $75 figure from one covering analyst dated August 16, 2026. Separately, Fintel reported in mid-September that an aggregate of analyst targets averaged about $76.50, within a $75.75–$78.75 range. Earlier in 2026, Roth MKM's Jonathan Aschoff carried a materially lower $3.00 Buy target (reduced from $8.00 in March 2026). Because current coverage is essentially one attributable target rather than a broad, dated consensus, this article treats $75 as a publicly discussed objective, not a robust analyst consensus, and the target comes from public discussion rather than a firm multi-analyst average.
The stock closed near $5.60 on October 29, 2026, with a market capitalization of roughly $11.5 million. Reaching $75 would require an advance of about 1,239% — a very large move. The shares have already demonstrated extreme swings: they surged from under $0.25 in early September 2026 to above $11 within roughly a week, then retraced toward the current level, with a 52-week range of $4.91 to $28.75. A path toward $75 would almost certainly depend on positive Phase 1 data readouts for GTBP's GTB-3650 (CD33-targeting, for myeloid leukemias) and GTB-5550 (B7-H3-targeting, for solid tumors), followed by a substantial re-rating of the company's valuation. With no revenue and a thin cash balance, any such move would likely hinge on clinical catalysts and new capital rather than fundamentals alone.
The company's TriKE (Tri-specific Killer Engager) and Dual Targeting TriKE platforms target natural killer cells against cancer and offer a differentiated scientific story. In September 2026, GTBP announced FDA clearance of a new IND for GTB-5550 in multiple myeloma under an investigator-sponsored trial, and in late October it was selected for an oral presentation at the SITC 2026 Annual Meeting. Encouraging Phase 1 dose-escalation updates, anticipated in the second half of 2026, or new partnerships and non-dilutive funding could reinforce sentiment. Broad sector enthusiasm for novel immuno-oncology approaches may also provide a supportive backdrop for a speculative biotech.
The risks are substantial. GTBP is pre-revenue, reporting essentially zero product sales, and its independent auditor has expressed doubt about the company's ability to continue as a going concern. The company reported a quarterly GAAP net loss of about $4.5 million and held roughly $4.96 million in cash, a combination that points to continued financing needs and shareholder dilution. In October 2026 the company filed a resale registration covering up to about 13.5 million shares tied to recently issued preferred stock and warrants, adding to potential overhang. A failed or delayed trial readout, slow enrollment, further reverse-split-driven volatility, or a shift away from speculative micro-cap biotechs could all keep the stock well below $75.
The shares trade far below their 52-week high of $28.75, with major support near the 52-week low of $4.91 set in early September 2026. The September spike above $11 stands out as a notable prior high and potential resistance zone, with the $28.75 level marking the next durable overhead reference. The $75 target sits well above every meaningful trading level in the stock's recent history, underscoring how much would need to change for it to be approached.
Single-analyst price targets generally reflect a roughly 12-month research horizon, though no specific timeframe is stated for the $75 figure. Investors should watch the GTB-3650 and GTB-5550 Phase 1 updates expected in the second half of 2026, the SITC presentation, any new financing or partnership announcements, and the next quarterly earnings report, which TradingView schedules for November 11, 2026. Changes in the covering analyst's rating or target, enrollment updates, and cash-burn disclosures will matter more than short-term price fluctuations.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals as market conditions, technical behavior, and AI-driven analysis evolve. For a highly volatile name like GTBP, such tools can help traders discover opportunities, monitor positions, and spot changing trends more efficiently than manual chart-watching alone. Explore the AI Daily Buy/Sell Signals to see how automated analysis can complement your own research.
Whether GT Biopharma can reach $75 depends on clinical catalysts and financing far more than on current fundamentals. The $75 objective comes from a single analyst's displayed target rather than a broad consensus, and the roughly 1,239% move required is very large. Positive Phase 1 data and new capital could support a re-rating, while ongoing losses, a going-concern warning, and dilution represent significant obstacles. Because analyst views have been sparse and inconsistent — ranging from a $3 Roth MKM target earlier in 2026 to the current $75 figure — investors should monitor trial readouts, financing, and any analyst revisions rather than treat the target as a forecast.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, GTBP has been loosely correlated with SLGL. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if GTBP jumps, then SLGL could also see price increases.
| Ticker / NAME | Correlation To GTBP | 1D Price Change % | ||
|---|---|---|---|---|
| GTBP | 100% | +1.63% | ||
| SLGL - GTBP | 33% Loosely correlated | +0.70% | ||
| AMRN - GTBP | 33% Poorly correlated | -0.08% | ||
| MDGL - GTBP | 32% Poorly correlated | +0.16% | ||
| VKTX - GTBP | 31% Poorly correlated | +5.91% | ||
| XBIO - GTBP | 31% Poorly correlated | +0.95% | ||
More | ||||